| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07545681 | A Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. Falciparum Malaria | PHASE2 | NOT YET_RECRUITING | 70 | — | — | Apr 20, 2026 | Jul 22, 2027 | Apr 22, 2026 | - | — |
A SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant; abnormal pregnancy outcomes; or any other situation according to medical or scientific judgment. The intensity of SAEs is assessed as per the Division of Acquired Immunodeficiency Syndrome (DAIDS) criteria Version 2.1 where grades are defined based on numeric criteria as follows Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: potentially life-threatening; Grade 5: death. A higher grade indicates greater severity. Any = occurrence of the event regardless of intensity grade and treatment relationship. Treatment related = occurrence of the event which, in the investigator's opinion, is related to the administered treatment regardless of the intensity grade.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. The intensity of non-serious AEs is assessed using the DAIDS criteria Version 2.1 where grades are defined based on numeric criteria as follows Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: potentially life-threatening; Grade 5: death. A higher grade indicates greater severity. Any = occurrence of the event regardless of intensity grade and treatment relationship. Treatment related = occurrence of the event which, in the investigator's opinion, is related to the administered treatment regardless of the intensity grade.
| Arm | Type | Description |
|---|---|---|
| Cohort 1_Single Dose | EXPERIMENTAL | Participants receive a single GSK3772701 600 mg dose on Day 1. |
| Cohort 2_ Single Dose | EXPERIMENTAL | Participants receive a single GSK3772701 900 mg dose on Day 1. |
| Cohort 3_ Repeat Dose | EXPERIMENTAL | Participants receive a daily 150 mg dose of GSK3772701 on Day 1 and Day 2. |
| Cohort 4_ Repeat Dose | EXPERIMENTAL | Participants receive a daily 400 mg dose of GSK3772701 on Day 1 and Day 2. |
| Cohort 5_ Repeat Dose | EXPERIMENTAL | Participants receive a daily 50 mg dose of GSK3772701 on Day 1, Day 2 and Day 3. |
| Name | Type | Description |
|---|---|---|
| GSK3772701 600 mg | DRUG | A 600 mg dose of GSK3772701 administered orally, as 4 capsules of 150 mg. |
| GSK3772701 900 mg | DRUG | A 900 mg dose of GSK3772701 administered orally, as 6 capsules of 150 mg. |
| GSK3772701 150 mg | DRUG | A daily 150 mg dose of GSK3772701 administered orally on Day 1 and Day 2, as 1 capsule. |
| GSK3772701 400 mg | DRUG | A daily 400 mg dose of GSK3772701 administered orally on Day 1 and Day 2, as 2 capsules of 150 mg and 1 capsule of 100 mg. |
| GSK3772701 50 mg | DRUG | A daily 50 mg dose of GSK3772701 administered orally on Day 1, Day 2 and Day 3, as 1 capsule. |
Inclusion Criteria: * Male and female patients aged 18 to 65 years. * Presence of malaria due to mono-infection with P. falciparum confirmed by: * Fever, as defined by axillary temperature \>=37.5°C or oral/tympanic temperature \>=38°C and, * Microscopically confirmed P. falciparum malaria par...